The understanding of glioma disease has significantly advanced through the application of genetic and molecular profiling techniques on brain tumour tissue. Molecular biomarkers have gained a crucial role in glioma diagnosis, driving groundbreaking changes in the disease classification as standardised by the 2016 and 2021 World Health Organisation (WHO) Classification of Tumours of the Central Nervous System. Recent insights from large-scale multi-omics databases, such as The Cancer Genome Atlas (TCGA), have enriched our comprehension of this cancer type. However, given the evolution of glioma classification, retrospective databases may contain outdated annotations, suboptimal for research. To address this issue, we propose two methods for updating the tumor classification of TCGA glioma samples according to the 2016 and 2021 WHO guidelines, through the integration of open-access curated molecular profiling data. Respectively, our Method-2016 and Method-2021 allowed for the diagnostic update of 98% and 87% of cases. The proposed reclassification pipelines, provided in R scripts, enable straightforward reproduction or customisation upon new WHO guideline releases.
The understanding of glioma disease has been evolving drastically with dedicated research into the genetic and molecular profiling of glioma tumour tissue. Molecular biomarkers have gained progressive and substantial importance in providing diagnostic information, leading to groundbreaking changes in the tumour classification system, criteria and taxonomy standardised by the 2016 and 2021 editions of the World Health Organization Classification of Tumours of the Central Nervous System’s guidelines (WHO-2016 and WHO-2021, respectively). Some of the insights into glioma disease derived from extensive research on open-source multi-omics databases, such as the Cancer Genome Atlas (TCGA). However, given the substantial changes in glioma classification, retrospective databases may harbour outdated diagnostic annotations, suboptimal for further research. Here we propose two methods for updating the tumour classification of TCGA glioma samples in accordance with WHO-2016 and WHO-2021 guidelines, through the integration of curated molecular profiling information. Our methods allowed for the diagnostic update of 98% and 87% of evaluated TCGA glioma cases according to WHO-2016 and -2021, respectively, and highlighted changes in patient-specific diagnosis across both guidelines’ editions. Our reclassification pipelines are provided in R scripts, facilitating direct reproduction or tailoring upon new releases of WHO guidelines.
Gliomas are primary malignant brain tumors with poor survival and high resistance to available treatments. Improving the molecular understanding of glioma and disclosing novel biomarkers of tumor development and progression could help to find novel targeted therapies for this type of cancer. Public databases such as The Cancer Genome Atlas (TCGA) provide an invaluable source of molecular information on cancer tissues. Machine learning tools show promise in dealing with the high dimension of omics data and extracting relevant information from it. In this work, network inference and clustering methods, namely Joint Graphical lasso and Robust Sparse K-means Clustering, were applied to RNA-sequencing data from TCGA glioma patients to identify shared and distinct gene networks among different types of glioma (glioblastoma, astrocytoma, and oligodendroglioma) and disclose new patient groups and the relevant genes behind groups’ separation. The results obtained suggest that astrocytoma and oligodendroglioma have more similarities compared with glioblastoma, highlighting the molecular differences between glioblastoma and the others glioma subtypes. After a comprehensive literature search on the relevant genes pointed our from our analysis, we identified potential candidates for biomarkers of glioma. Further molecular validation of these genes is encouraged to understand their potential role in diagnosis and in the design of novel therapies.
Prostate cancer (PCa) is one of the most frequent cancer in male population. Androgen deprivation therapy is the first-line strategy for the metastatic stage of the disease, but, inevitably, PCa develops resistance to castration (CRPC), becoming incurable. In recent years, clinical trials are testing the efficacy of anti-CTLA4 on CRPC. However, this tumor seems to be resistant to immunotherapies that are very effective in other types of cancers, and, so far, only the dendritic cell vaccine sipuleucel-T has been approved. In this work, we employ a mathematical model of CRPC to determine the optimal administration protocol of ipilimumab, a particular anti-CTLA4, as single treatment or in combination with the sipuleucel-T, by considering both the effect on tumor population and the drug toxicity. To this end, we first introduce a dose-depending function of toxicity, estimated from experimental data, then we define two different optimization problems. We show the results obtained by imposing different constraints, and how these change by varying drug efficacy. Our results suggest administration of high-doses for a brief period, which is predicted to be more efficient than solutions with prolonged low-doses. The model also highlights a synergy between ipilimumab and sipuleucel-T, which leads to a better tumor control with lower doses of ipilimumab. Finally, tumor eradication is also conceivable, but it depends on patient-specific parameters.
Tumor heterogeneity is a challenge to designing effective and targeted therapies. Glioma-type identification depends on specific molecular and histological features, which are defined by the official WHO classification CNS. These guidelines are constantly updated to support the diagnosis process, which affects all the successive clinical decisions. In this context, the search for new potential diagnostic and prognostic targets, characteristic of each glioma type, is crucial to support the development of novel therapies. Based on a TCGA glioma RNA-sequencing dataset updated according to the 2016 and 2021 WHO guidelines, we proposed a two-step variable selection approach for biomarker discovery. Our framework encompasses the graphical lasso algorithm to estimate sparse networks of genes carrying diagnostic information. These networks are then used as input for regularised Cox survival regression model, allowing the identification of a smaller subset of genes with prognostic value. In each step, the results derived from the 2016 and 2021 classes were discussed and compared. For both WHO glioma classifications, our analysis identifies potential biomarkers, characteristic of each glioma type. Yet, better results were obtained for the WHO CNS classification in 2021, thereby supporting recent efforts to include molecular data on glioma classification.
17 February 2025 in Computers in Biology and Medicine
Gliomas are highly heterogeneous tumors with generally poor prognoses. Leveraging multi-omics data and network analysis holds great promise in uncovering crucial signatures and molecular relationships that elucidate glioma heterogeneity. However, the complexity of the problem and the high dimensionality of the data increase the challenges of integrating information across various biological levels. This study develops a comprehensive framework aimed at identifying potential glioma-type-specific biomarkers through innovative variable selection and integrated network visualization. We designed a two-step framework for variable selection using sparse network estimation across various omics datasets. This framework incorporates MINGLE (Multi-omics Integrated Network for GraphicaL Exploration), a novel methodology designed to merge distinct multi-omics information into a single network, enabling the identification of underlying relations through an innovative integrated visualization. The analysis was conducted using glioma omics datasets, with patients grouped based on the latest glioma classification guidelines. Our investigation of the glioma data led to the identification of variables potentially serving as glioma-type-specific biomarkers. The integration of multi-omics data into a single network through MINGLE facilitated the discovery of molecular relationships that reflect glioma heterogeneity, supporting the biological interpretation. Scripts and files for reproducing the analysis or adapting it to other applications, are available in R software.